EQUITY RESEARCH MEMO

Biotage (BIOT)

Generated 5/11/2026

Executive Summary

Conviction (model self-assessment)70/100

Biotage is a leading global life sciences tools company headquartered in Uppsala, Sweden, specializing in separation and purification technologies for drug discovery, development, and analytical testing. With a strong portfolio of automated systems and high-quality consumables, Biotage empowers scientists to accelerate and simplify workflows in pharmaceutical and diagnostic laboratories. The company’s focus on intelligent workflow solutions positions it as a key enabler for the efficiency and productivity of R&D processes in the life sciences industry. Biotage has a proven track record of innovation and customer partnerships, with a broad installed base across academic, biotech, and pharma customers worldwide.

Upcoming Catalysts (preview)

  • Q3 2026Launch of next-generation purification system with AI-driven workflow optimization75% success
  • Q4 2026Expansion of consumables manufacturing capacity in Asia to meet growing demand80% success
  • Q2 2027Potential strategic acquisition of a complementary separation technology startup50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)